Proteon Therapeutics Inc (PRTO) Receives $3.33 Average Target Price from Brokerages

Shares of Proteon Therapeutics Inc (NASDAQ:PRTO) have been given an average rating of “Hold” by the six ratings firms that are covering the stock, reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $3.43.

PRTO has been the subject of several research reports. Robert W. Baird reissued a “hold” rating and issued a $2.00 price objective on shares of Proteon Therapeutics in a research report on Friday, November 10th. HC Wainwright reissued a “hold” rating and issued a $2.30 price objective on shares of Proteon Therapeutics in a research report on Wednesday, November 8th. Finally, Zacks Investment Research cut Proteon Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 18th.

Proteon Therapeutics (NASDAQ:PRTO) traded down $0.05 on Thursday, hitting $1.85. The stock had a trading volume of 30,787 shares, compared to its average volume of 106,395. Proteon Therapeutics has a 12 month low of $1.10 and a 12 month high of $2.75.

In other Proteon Therapeutics news, Director James E. Flynn acquired 110,557 shares of Proteon Therapeutics stock in a transaction dated Thursday, November 30th. The stock was bought at an average cost of $1.75 per share, with a total value of $193,474.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders bought 122,852 shares of company stock valued at $216,533 over the last three months. 36.30% of the stock is owned by company insiders.

A hedge fund recently bought a new stake in Proteon Therapeutics stock. RA Capital Management LLC acquired a new stake in Proteon Therapeutics Inc (NASDAQ:PRTO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics accounts for 0.2% of RA Capital Management LLC’s portfolio, making the stock its 22nd biggest holding. RA Capital Management LLC owned 7.59% of Proteon Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 50.05% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at

About Proteon Therapeutics

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply